Payment overview · 2025
General Payments
$533.72
31 reported records · 11 companies
Healthcare provider profile · identity verified
Jon Eric Chancellor, MD
Allopathic & Osteopathic Physicians|Family Medicine · KERRVILLE, TX · NPI 1598708794
Verified facts
What the public records show
CMS Open Payments records show Jon Eric Chancellor, MD received $533.72 in general payments during 2025 across 31 reported records.
ABBVIE INC. accounted for 39.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.42 | 39.0% | 13 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $93.23 | 17.5% | 5 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $60.02 | 11.2% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $38.36 | 7.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.28 | 5.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.59 | 4.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $20.03 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.50 | 3.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.36 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.04 | 2.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.89 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $533.72 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $181.75 | 12 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $93.23 | 5 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $60.02 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $38.36 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.28 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 350 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 101 |
| Lisinopril | Lisinopril | 311 | 91 |
| Losartan Potassium | Losartan Potassium | 272 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 72 |
| Montelukast Sodium | Montelukast Sodium | 255 | 69 |
| Gabapentin | Gabapentin | 224 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 63 |
| Simvastatin | Simvastatin | 201 | 53 |
| Metformin Hcl | Metformin Hcl | 198 | 54 |
| Omeprazole | Omeprazole | 195 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 169 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 42 |
| Celecoxib | Celecoxib | 147 | 37 |
| Trazodone Hcl | Trazodone Hcl | 145 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 54 |
| Tramadol Hcl | Tramadol Hcl | 132 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 30 |
| Allopurinol | Allopurinol | 117 | 38 |
| Eszopiclone | Eszopiclone | 115 | 30 |
| Meloxicam | Meloxicam | 108 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 19 |
| Alprazolam | Alprazolam | 98 | 24 |
| Furosemide | Furosemide | 97 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 33 |
| Potassium Chloride | Potassium Chloride | 92 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 89 | 51 |
| Sertraline Hcl | Sertraline Hcl | 88 | 31 |
| Ozempic | Semaglutide | 81 | 16 |
| Glimepiride | Glimepiride | 78 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 25 |
| Finasteride | Finasteride | 75 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 73 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 53 |
| Carvedilol | Carvedilol | 69 | 19 |
| Jardiance | Empagliflozin | 69 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 21 |
| Clonazepam | Clonazepam | 63 | 13 |
| Nifedipine Er | Nifedipine | 62 | 16 |
| Synthroid | Levothyroxine Sodium | 62 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 17 |
| Eliquis | Apixaban | 55 | 11 |
| Spironolactone | Spironolactone | 55 | 17 |
| Lorazepam | Lorazepam | 54 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | 15 |
| Ezetimibe | Ezetimibe | 45 | 13 |
| Atenolol | Atenolol | 43 | 12 |
| Azithromycin | Azithromycin | 42 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 19 |
| Diazepam | Diazepam | 41 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 11 |
| Temazepam | Temazepam | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Cefdinir | Cefdinir | 34 | 32 |
| Diclofenac Potassium | Diclofenac Potassium | 34 | 11 |
| Estradiol | Estradiol | 34 | 12 |
| Methocarbamol | Methocarbamol | 34 | 12 |
| Methylprednisolone | Methylprednisolone | 34 | 28 |
| Glipizide | Glipizide | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 20 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Baclofen | Baclofen | 31 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 27 |
| Ondansetron Odt | Ondansetron | 31 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Prednisone | Prednisone | 27 | 13 |
| Ramipril | Ramipril | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 11 |
| Ketoconazole | Ketoconazole | 24 | 17 |
| Levofloxacin | Levofloxacin | 24 | 19 |
| Tramadol Hcl Er | Tramadol Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Colchicine | Colchicine | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Mupirocin | Mupirocin | 18 | 12 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Butrans | Buprenorphine | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $533.72 · 31 records | ABBVIE INC. | INJECTAFER, INSPIRE, JOURNAVX, Kerendia, MOUNJARO, QULIPTA, Senza, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error